GlassScriptPhysician profile
Angela D Nicastro
NPI 1740513589
$10,699.54
in general payments reported to CMS, 2019-2025
43 companies · $2,428 in 2025
The $2,428 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,031 · 2022: $2,047 · 2023: $1,931 · 2024: $2,263 · 2025: $2,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,560 · Education: $61.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,559.76 |
| Education | $61.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,439.15 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $1,272.14 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,151.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,109.95 | 2021-2025 | |
| Pfizer INC. | $811.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $714.69 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $331.21 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.69 | 2021-2025 | Jardiance, Spiriva Respimat |
| Merck Sharp & Dohme LLC | $313.13 | 2021-2025 | Gardasil 9, Verquvo, Vaxneuvance |
| Lundbeck LLC | $310.42 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $237.94 | 2021-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $235.84 | 2022 | |
| Janssen Pharmaceuticals, INC | $220.25 | 2021-2024 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $196.61 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $195.62 | 2021-2025 | Xifaxan, Trulance |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Nicastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.